{
    "name": "doxazosin",
    "comment": "Rx",
    "other_names": [
        "Cardura",
        "Cardura XL"
    ],
    "classes": [
        "BPH",
        "Alpha Blockers"
    ],
    "source": "https://reference.medscape.com/drug/cardura-xl-doxazosin-342343",
    "pregnancy": {
        "common": [
            "Not indicated for use in females or for the treatment of hypertension; the limited available data in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage; no adverse developmental outcomes were observed in animal reproduction studies with oral administration to pregnant rats and rabbits at doses of up to 10 and 4 times, respectively, the 12 mg/day recommended dose; postnatal development was delayed in rats at a dose of 8 times the 12 mg/day recommended dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Present in human milk; there is no information on effects on breastfed infant or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to doxazosin or other quinazolines"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use with caution in liver disease or recent cerebrovascular accident (CVA)",
                "Rule out prostate cancer before initiating therapy",
                "May cause first-dose syncope or sudden loss of consciousness",
                "Risk of orthostatic hypotension (dose dependent)",
                "Potential for hypotension, dry mouth, and urinary complications in elderly",
                "Priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation) rarely reported (probably less frequently than once in every several thousand patients), with alpha-1 antagonists, including doxazosin; because condition can lead to permanent impotence if not promptly treated, patients must be advised about seriousness of condition",
                "Concomitant use of other antihypertensives (additive hypotensive effects)",
                "Extended-release form not indicated for hypertension",
                "Concomitant administration of immediate-release form with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension",
                "May increase the risk of heart failure by exacerbating underlying myocardial dysfunction by Î²1Receptor stimulation with increases in renin and aldosterone",
                "May cause CNS depression, which may impair ability to operate heavy machinery and performing tasks that require mental alertness",
                "Allergic reactions, including urticaria, rash, angioedema, pruritus, and respiratory symptoms may occur",
                "Intraoperative floppy iris syndrome reported in cataract surgery patients who received alph1-blocker therapy; discontinuing alpha-blocker therapy prior to surgery does not appear to be of benefit",
                "Decreases in white blood cells (WBC) and neutrophil count reported; WBC and neutrophil counts returned to normal following discontinuation of therapy"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "sildenafil",
            "description": {
                "common": "sildenafil increases effects of doxazosin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "doxazosin, tamsulosin.\nEither increases effects of the other by additive vasodilation. Avoid or Use Alternate Drug. Risk of hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vardenafil",
            "description": {
                "common": "vardenafil increases effects of doxazosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yohimbe",
            "description": {
                "common": "yohimbe increases effects of doxazosin by pharmacodynamic synergism. Contraindicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "doxazosin and acebutolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of doxozosin may be enhanced."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "aceclofenac decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "acemetacin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases effects of doxazosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "alfuzosin and doxazosin both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, doxazosin.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "doxazosin and amlodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and doxazosin both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "aspirin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "aspirin rectal decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "doxazosin and atenolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of doxazosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "doxazosin and betaxolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "doxazosin and bisoprolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "captopril, doxazosin.\nEither increases effects of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbidopa",
            "description": {
                "common": "carbidopa increases effects of doxazosin by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "doxazosin and carvedilol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "doxazosin and celiprolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "choline magnesium trisalicylate decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clevidipine",
            "description": {
                "common": "doxazosin and clevidipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "clonidine, doxazosin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "diclofenac decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "diflunisal decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "doxazosin and diltiazem both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "duvelisib will increase the level or effect of doxazosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enalapril",
            "description": {
                "common": "enalapril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "doxazosin and esmolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of doxozosin may be enhanced."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "etodolac decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "doxazosin and felodipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "fenoprofen decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "flurbiprofen decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosinopril",
            "description": {
                "common": "fosinopril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "ibuprofen decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "ibuprofen IV decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone increases effects of doxazosin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imidapril",
            "description": {
                "common": "imidapril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "indomethacin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "doxazosin and isradipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "ketoprofen decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "ketorolac decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "ketorolac intranasal decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "doxazosin and labetalol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "levodopa increases effects of doxazosin by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisinopril",
            "description": {
                "common": "lisinopril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "lornoxicam decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone increases effects of doxazosin by Other (see comment). Use Caution/Monitor. \nComment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc, doxazosin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "mefenamic acid decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "meloxicam decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "doxazosin and metoprolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moexipril",
            "description": {
                "common": "moexipril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "doxazosin and moxisylyte both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "nabumetone decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "doxazosin and nadolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "naproxen decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "doxazosin and nebivolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "doxazosin and nicardipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "doxazosin and nifedipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of doxazosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased bradycardia, hypotension, or dizziness. If needed, temporarily pause the antihypertensive drug. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "doxazosin and nisoldipine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, doxazosin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "oxaprozin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymetazoline topical",
            "description": {
                "common": "oxymetazoline topical increases and doxazosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "parecoxib decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "doxazosin and penbutolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perindopril",
            "description": {
                "common": "perindopril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "doxazosin and phenoxybenzamine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentolamine",
            "description": {
                "common": "doxazosin and phentolamine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "doxazosin and pindolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "piroxicam decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "doxazosin and prazosin both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "doxazosin and propranolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of doxozosin may be enhanced."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "pseudoephedrine decreases effects of doxazosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinapril",
            "description": {
                "common": "quinapril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramipril",
            "description": {
                "common": "ramipril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "salicylates (non-asa) decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "salsalate decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "silodosin",
            "description": {
                "common": "doxazosin and silodosin both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "doxazosin and sotalol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of doxozosin may be enhanced."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "sulfasalazine decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "sulindac decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tadalafil",
            "description": {
                "common": "tadalafil increases effects of doxazosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terazosin",
            "description": {
                "common": "doxazosin and terazosin both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "doxazosin and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolfenamic acid",
            "description": {
                "common": "tolfenamic acid decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolmetin",
            "description": {
                "common": "tolmetin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trandolapril",
            "description": {
                "common": "trandolapril, doxazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "doxazosin and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "doxazosin and zotepine both increase  anti-hypertensive channel blocking. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butcher's broom",
            "description": {
                "common": "doxazosin, butcher's broom.\nEither decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "doxazosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenylephrine",
            "description": {
                "common": "doxazosin, phenylephrine.\nEither decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "doxazosin, phenylephrine PO.\nEither decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tizanidine",
            "description": {
                "common": "tizanidine increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treprostinil",
            "description": {
                "common": "treprostinil increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "5-19"
        },
        {
            "name": "Fatigue",
            "percent": "8-12"
        },
        {
            "name": "Headache",
            "percent": "6-10"
        },
        {
            "name": "Vertigo",
            "percent": "7"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "5"
        },
        {
            "name": "URTI",
            "percent": "3-4"
        },
        {
            "name": "Edema",
            "percent": "3"
        },
        {
            "name": "Rhinitis",
            "percent": "1-3"
        },
        {
            "name": "Dyspnea",
            "percent": "2"
        },
        {
            "name": "Abdominal pain",
            "percent": "1-2"
        },
        {
            "name": "Hypotension",
            "percent": "1-2"
        },
        {
            "name": "Nausea",
            "percent": "0.3-2"
        },
        {
            "name": "Orthostatic hypotension",
            "percent": "1"
        },
        {
            "name": "dose related",
            "percent": "1"
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Palpitations",
            "percent": null
        },
        {
            "name": "Autonomic Nervous System",
            "percent": null
        },
        {
            "name": "Priapism",
            "percent": null
        },
        {
            "name": "Cardiovascular System",
            "percent": null
        },
        {
            "name": "Cerebrovascular accidents",
            "percent": null
        },
        {
            "name": "dizziness postural",
            "percent": null
        },
        {
            "name": "myocardial infarction",
            "percent": null
        },
        {
            "name": "Central and Peripheral Nervous System",
            "percent": null
        },
        {
            "name": "Hypoesthesia",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "Endocrine System",
            "percent": null
        },
        {
            "name": "Gynecomastia",
            "percent": null
        },
        {
            "name": "Gastrointestinal System",
            "percent": null
        },
        {
            "name": "Gastrointestinal obstruction",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "General Body System",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "hot flushes",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "Heart Rate",
            "percent": null
        },
        {
            "name": "Rhythm",
            "percent": null
        },
        {
            "name": "Bradycardia",
            "percent": null
        },
        {
            "name": "cardiac arrhythmias",
            "percent": null
        },
        {
            "name": "Hematopoietic",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "purpura",
            "percent": null
        },
        {
            "name": "thrombocytopenia",
            "percent": null
        },
        {
            "name": "Liver",
            "percent": null
        },
        {
            "name": "Biliary System",
            "percent": null
        },
        {
            "name": "Abnormal liver function tests",
            "percent": null
        },
        {
            "name": "hepatitis",
            "percent": null
        },
        {
            "name": "hepatitis cholestatic",
            "percent": null
        },
        {
            "name": "jaundice",
            "percent": null
        },
        {
            "name": "Musculoskeletal System",
            "percent": null
        },
        {
            "name": "Muscle cramps",
            "percent": null
        },
        {
            "name": "muscle weakness",
            "percent": null
        },
        {
            "name": "Psychiatric",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "anorexia",
            "percent": null
        },
        {
            "name": "nervousness",
            "percent": null
        },
        {
            "name": "Respiratory System",
            "percent": null
        },
        {
            "name": "Bronchospasm aggravated",
            "percent": null
        },
        {
            "name": "Skin Disorders",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "skin rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "Special Senses",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "intraoperative Floppy Iris Syndrome",
            "percent": null
        },
        {
            "name": "Urinary System",
            "percent": null
        },
        {
            "name": "Hematuria",
            "percent": null
        },
        {
            "name": "micturition disorder",
            "percent": null
        },
        {
            "name": "micturition frequency",
            "percent": null
        },
        {
            "name": "nocturia",
            "percent": null
        },
        {
            "name": "polyuria",
            "percent": null
        }
    ]
}